FrancophonIA/ELRC3.0 huggingface dataset:
English: Ravicti received a marketing authorisation valid throughout the EU on 27 November 2015 Further information on Ravicti can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/ravicti
Estonian: Lisateave Ravicti kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/ravicti Kokkuvõtte viimane uuendus: 01.2019.
English: It can only be obtained with a prescription and should be prescribed by a doctor who has experience in treating patients with urea cycle disorders.
Estonian: Ravictiga ravi tohib määrata uureatsükli häiretega patsientide ravis kogenud arst.
English: Ravicti is effective in reducing the blood level of ammonia in patients with urea cycle disorders.
Estonian: Ravicti on uureatsükli häiretega patsientidel efektiivne vere ammoniaagisisalduse vähendamisel.
English: How is Ravicti used?
Estonian: Kuidas Ravictit kasutatakse?
English: Ravicti contains the active substance glycerol phenylbutyrate.
Estonian: Ravicti sisaldab toimeainena glütseroolfenüülbutüraati.
English: Patients with urea cycle disorders are not able to get rid of waste nitrogen from the body because they lack some liver enzymes.
Estonian: Uureatsükli häiretega patsientide organismis puuduvad teatud maksaensüümid, mille tõttu ei eritu organismist jääklämmastik.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Orphacol on 12 September 2013.
Estonian: Euroopa Komisjon andis Orphacoli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 12. septembril 2013.
English: Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.
Estonian: Euroopa Ravimiamet vaatab kogu uue teabe igal aastal läbi ja vajaduse korral uuendab käesolevat kokkuvõtet.
English: A risk management plan has been developed to ensure that Orphacol is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Orphacoli võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Orphacol?
Estonian: Mis meetmeid võetakse, et tagada Orphacoli ohutu ja efektiivne kasutamine?
English: Other information about Orphacol
Estonian: Muu teave Orphacoli kohta
English: Orphacol is available as capsules and should be taken every day at approximately the same time, with a meal.
Estonian: Orphacoli turustatakse kapslitena ja seda võetakse iga päev koos toiduga enam-vähem samal ajal.
English: This is a summary of the European public assessment report (EPAR) for Orphacol.
Estonian: See on ravimi Orphacol Euroopa avaliku hindamisaruande kokkuvõte.
English: Because cholic acid is a well-known substance, and its use in these enzyme deficiencies is well established, the applicant presented data from the scientific literature.
Estonian: Et koolhape on tuntud toimeaine ja selle kasutamine nimetatud ensüümide vaeguse korral on hästi teada, esitas müügiloa taotleja andmeid teaduskirjandusest.
English: It must not be taken by patients already taking phenobarbital, a medicine used to treat epilepsy.
Estonian: Seda ei tohi samuti kasutada patsiendid, kes saavad ravi fenobarbitaaliga, mida kasutatakse epilepsia raviks.
English: What is Orphacol and what is it used for?
Estonian: Mis on Orphacol ja milleks seda kasutatakse?
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Orphacol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Orphacoli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The full EPAR for Orphacol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Orphacoli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The Committee for Medicinal Products for Human Use (CHMP) noted that the use of cholic acid to treat inborn errors in primary bile acid synthesis was well established in medical practice and documented in the scientific literature, although the number of documented cases was low due to the rarity of the condition.
Estonian: Inimravimite komitee märkis, et koolhappe kasutamine primaarsete sapphapete sünteesi kaasasündinud häirete raviks on meditsiinipraktikas hästi teada ja teaduskirjanduses dokumenteeritud, ehkki dokumenteeritud ravijuhtude arv on haiguse harva esinemise tõttu väike.
English: The side effects seen with Orphacol were diarrhoea, pruritus (itching), increases in transaminases (liver enzymes) and possibly gallstones, although their frequency could not be reliably estimated from the available limited data.
Estonian: Orphacoli kasutamisel täheldatud kõrvalnähud on kõhulahtisus, kihelus, transaminaaside (maksaensüümide) sisalduse suurenemine ja tõenäoliselt ka sapikivid, ehkki nende esinemissagedust ei saanud olemasolevate piiratud andmete alusel hinnata.
English: This means that because the disease is rare, it has not been possible to obtain complete information about Orphacol.
Estonian: Orphacoli müügiluba anti erandkorras, sest kuna haigus esineb harva, ei olnud võimalik saada Orphacoli kohta täielikku teavet.
English: The applicant presented data on 49 patients with inborn errors in primary bile acid synthesis, taken from the scientific literature (38 patients with 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency and 11 patients with Δ4-3-Oxosteroid-5β-reductase deficiency).
Estonian: Müügiloa taotleja esitas teaduskirjanduse andmed 49 patsiendi kohta, kellel oli sapphapete sünteesi kaasasündinud häire (38 patsienti 3βhüdroksü-Δ5-C27-steroidi oksidoreduktaasi vaegusega ja 11 patsienti Δ4-3-oksüsteroid-5β-reduktaasi vaegusega).
English: Orphacol should not be used in people who may be hypersensitive (allergic) to cholic acid or any of the other ingredients.
Estonian: Orphacoli ei tohi kasutada isikud, kes on koolhappe või ravimi mõne muu koostisaine suhtes ülitundlikud (allergilised).
English: The cholic acid contained in Orphacol replaces the patient's missing cholic acid.
Estonian: Orphacolis sisalduv koolhape asendab puuduvat koolhapet.
English: It decided that based on the evidence from the scientific literature Orphacol's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee teaduskirjanduses avaldatud tõendusmaterjalide alusel, et Orphacoli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Why is Orphacol approved?
Estonian: Miks Orphacol heaks kiideti?
English: Treatment should be stopped if liver function does not improve within three months.
Estonian: Kui maksafunktsioon ei parane 3-kuulise ravi jooksul, tuleb ravi katkestada.
English: What information is still awaited for Orphacol?
Estonian: Mis teavet Orphacoli kohta veel oodatakse?
English: Orphacol is used in patients who do not have enough of two specific liver enzymes (3β-Hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-Oxosteroid-5β-reductase).
Estonian: Orphacoli kasutatakse patsientidel, kellel on kahe spetsiifilise maksaensüümi (3β-hüdroksü-Δ5-C27-steroidi oksidoreduktaasi või Δ4-3-oksüsteroid5β-reduktaasi) vaegus.
English: The company that makes Orphacol will also provide doctors in all Member States who will use Orphacol with a pack containing product literature and information regarding the correct diagnosis of these disease conditions, the risks of side effects and how to use the medicine properly.
Estonian: Orphacoli turustav ettevõte varustab kõigis liikmesriikides Orphacoli välja kirjutavad arstid teabepakmega, mis sisaldab õppematerjale ja teavet kõnealuste haigusseisundite õige diagnoosimise ja ravi, samuti kõrvaltoimete riski ja ravimi õige kasutamise kohta.
English: It is not intended to provide practical advice on how to use Orphacol.
Estonian: Hindamisaruandes ei anta Orphacoli kasutamise praktilisi nõuandeid.
English: It is used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile.
Estonian: Orphacoli kasutatakse täiskasvanute ja vähemalt 1 kuu vanuste laste raviks, kellel on geneetiline defekt, mille tõttu nad ei ole võimelised sappi tootma.
English: Because the number of patients with inborn errors in primary bile acid synthesis is low, the condition is considered ‘rare', and Orphacol was designated an ‘orphan medicine' (a medicine used in rare diseases) on 18 December 2002.
Estonian: Et primaarsete sapphapete sünteesi kaasasündinud häiretega patsientide arv on väike ja see haigus esineb harva, nimetati Orphacol 18. detsembril 2002 harvikravimiks.
English: In the scientific literature, cholic acid treatment was shown to reduce the amount of abnormal bile acids in patients, to restore the normal functions of the liver and to help delay or prevent the need for a liver transplant.
Estonian: Teaduskirjanduses on näidatud, et ravi koolhappega vähendab patsientidel ebanormaalsete sapphapete kogust, taastab normaalse maksafunktsiooni ja aitab edasi lükata või ära hoida maksasiirdamise vajadust.
English: Since Orphacol has been approved under exceptional circumstances, the company that markets Orphacol will establish a database of patients treated with Orphacol to monitor the safety and effectiveness of the treatment, and will submit the results to the CHMP at regular, specified intervals.
Estonian: Et Orphacol kiideti heaks erandkorras, loob Orphacoli turustav ettevõte Orphacoliga ravitavate patsientide andmebaasi, et jälgida ravi ohutust ja efektiivsust, ning esitab need andmed kokkulepitud ajavahemike tagant inimravimite komiteele.
English: What are the risks associated with Orphacol?
Estonian: Mis riskid Orphacoliga kaasnevad?
English: EPAR summary for the public
Estonian: Kokkuvõte üldsusele koolhape
English: This makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid.
Estonian: Seetõttu ei ole selliste patsientide maks võimeline tootma piisavas koguses sapi peamisi komponente, nn primaarseid sapphappeid, sealhulgas koolhapet.
English: This helps to decrease the production of abnormal bile acids and contributes to the normal activity of bile in the digestive system, thereby relieving the symptoms of the condition.
Estonian: See aitab vähendada ebanormaalsete sapphapete tootmist ja aitab taastada sapi normaalset funktsiooni seedesüsteemis, vähendades sel teel haigussümptomeid.
English: The daily dose is between 5 and 15 mg per kg body weight, adjusted for each patient according to the state of their bile acid, with a minimum daily dose of 50 mg and a maximum of
Estonian: Ööpäevane annus on vahemikus 5-15 mg kehakaalu kg kohta ja seda kohandatakse iga patsiendi jaoks olenevalt tema sapphapete profiilist.
English: When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.
Estonian: Kui primaarseid sapphappeid ei ole piisavas koguses, toodab maks nende asemel ebanormaalseid sapphappeid, mis võivad kahjustada maksa ja põhjustada eluohtlikku maksapuudulikkust.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Orphacol, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Orphacoli ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: How does Orphacol work?
Estonian: Kuidas Orphacol toimib?
English: Cholic acid is the main primary bile acid produced by the liver.
Estonian: Koolhape on peamine maksas toodetav primaarne sapphape.
English: 500 mg. For small children who cannot swallow capsules, the contents can be mixed in with infant formula or juice.
Estonian: Minimaalne ööpäevane annus on 50 mg ja maksimaalne ööpäevane annus 500 mg. Väikestel lastel, kes ei ole võimelised kapsleid neelama, võib segada kapsli sisu imikutoidu või mahla sisse.
English: For practical information about using Orphacol, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Orphacoli kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Orphacol, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Orphacoliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: How is Orphacol used?
Estonian: Kuidas Orphacoli kasutatakse?
English: It compared the outcomes of 28 patients who received cholic acid with others who were given different bile acids or did not receive bile acid treatment.
Estonian: Nendes kirjandusandmetes võrreldi koolhappega ravitud 28 patsiendi ravitulemusi teiste patsientide ravitulemustega, keda raviti muude sapphapetega või kes ei saanud sapphapperavi.
English: What benefits of Orphacol have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Orphacoli kasulikkus?
English: Orphacol is a medicine containing cholic acid, a substance found in the bile which is used to digest fats.
Estonian: Koolhape on aine, mida leidub sapis ja mis aitab seedida rasvu.
English: Orphacol cholic acid
Estonian: Orphacol on retseptiravim.
English: The medicine can only be obtained with a prescription and treatment with Orphacol should be started and supervised by a doctor specialised in liver disease.
Estonian: Ravi Orphacoliga peab alustama maksahaiguste ravile spetsialiseerunud arst ja see peab toimuma tema järelevalve all.
English: The effects last for at least 12 hours.
Estonian: Toime kestab vähemalt 12 tundi.
English: Recent use of these medicines might increase the risk of
Estonian: Nende ravimite hiljutisel kasutamisel võib suureneda risk, et
English: Frequency not known, but may also occur:
Estonian: Esinemissagedus teadmata, kuid võivad samuti esineda
English: It is not known if this was due to pharmacogenetic or other factors.
Estonian: Ei ole teada, kas see on tingitud farmakogeneetilistest või muudest teguritest.
English: This makes it easier for air to get in and out.
Estonian: See lihtsustab õhu sisse- ja väljavoolu.
English: Take care not to block the air vents.
Estonian: Olge ettevaatlik ja ärge blokeerige õhuavasid.
English: Just take your next dose at the usual time.
Estonian: Võtke lihtsalt järgmine annus tavalisel
English: These side effects may include any of the following:
Estonian: Need kõrvaltoimed võivad hõlmata ükskõik millist järgmistest:
English: Depression, aggression (predominantly in children)
Estonian: Depressioon, agressioon (peamiselt lastel)
English: Note that it is important that you breathe in forcefully.
Estonian: Pange tähele, et oluline on tugevalt sisse hingata.
English: This study was not designed to investigate the effect on exacerbations.
Estonian: See uuring ei olnud mõeldud ägenemistele avaldatava toime uurimiseks.
English: Caution is recommended and long-term treatment with such drugs should if possible be avoided.
Estonian: Tuleb olla ettevaatlik ja pikaajalist ravi selliste ravimitega tuleb võimalusel vältida.
English: Hold your breath for 10 seconds or as long as you comfortably can.
Estonian: Hoidke oma hinge kinni, kas 10 sekundit või nii kaua kui on mugav.
English: Breathe in through your mouth as deeply and as forcefully as you can.
Estonian: Hingake sisse läbi suu, nii sügavalt ja tugevalt, kui suudate.
English: Mogilska 80 Str. 31-546 Kraków, Poland
Estonian: Mogilska 80 Str. 31-546 Kraków, Poola
English: These are often used to treat asthma.
Estonian: Neid kasutatakse sageli astma raviks.
English: There are no data in humans.
Estonian: Inimeste kohta andmed puuduvad.
English: • Headache - this usually gets better as treatment continues.
Estonian: • Peavalu - see leeveneb üldjuhul ravi jätkudes.
English: Risk in bold figures is statistically significant at the 95% level.
Estonian: Rasvases kirjas märgitud risk on 95% tasemel statistiliselt oluline.
English: Vision, blurred (see also section 4.4)
Estonian: Nägemise ähmastumine (vt ka lõik 4.4)
English: See section 4.4: “Adrenal function”.
Estonian: Vt lõik 4.4, „Neerupealiste funktsioon”.
English: Frequencies were derived from clinical trial data.
Estonian: Esinemissagedused pärinevad kliiniliste uuringute andmetest.
English: (*=could not be calculated because of no events in placebo group.
Estonian: (*=ei olnud võimalik välja arvestada, kuna platseeborühmas juhte ei esinenud.
English: For pharmacokinetic purposes each component can be considered separately.
Estonian: Farmakokineetika eesmärgil võib hinnata mõlemat koostisainet eraldi.
English: The Salmeterol Multi-center Asthma Research Trial (SMART)
Estonian: Salmeterooli mitmekeskuseline astma teadusuuring (Salmeterol Multi-Center Asthma Research Trial, SMART)
English: Treatment was stepped up every 12 weeks until **total control was achieved or the highest dose of study drug was reached.
Estonian: Annust suurendati iga 12 nädala järel kuni **täieliku kontrolli saavutamise või uuringuravimi suurima annuse kasutuselevõtuni.
English: Your inhaler is now ready
Estonian: Teie inhalaator on nüüd
English: Salmeterol/FP
Estonian: Salmeterool/FP
English: However, it should be noted that children and adolescents less than 16 years taking high doses of fluticasone propionate (typically ≥ 1000 micrograms/day) may be at particular risk.
Estonian: Sellegipoolest tuleb märkida, et lapsi ja noorukeid vanuses alla 16 eluaasta, kes võtavad suures annuses flutikasoonpropionaati (tavaliselt ≥ 1000 mikrogrammi/ööpäevas), võib ohustada eriti suur risk.
English: Latvija Sicor Biotech filiāle Latvijā
Estonian: Sicor Biotech filiāle Latvijā
English: Less than 5% of the dose is excreted in urine, mainly as metabolites.
Estonian: Vähem kui 5% annusest eritub uriiniga, peamiselt metaboliitidena.
English: A risk to breastfed newborns/infants cannot be excluded.
Estonian: Riski imetatavatele vastsündinutele/imikutele ei saa välistada.
English: • High blood pressure
Estonian: • kõrge vererõhk;
English: • For inhalations remaining from 20 downwards to ‘8', ‘6', ‘4', ‘2' the numbers are displayed in red on a white background.
Estonian: • Alates 20-st allesjäänud inhalatsioonist kuni arvudeni 8, 6, 4, 2 on numbrid märgitud punasega valgel taustal.
English: In general inhaled corticosteroids remain the first line treatment for most patients.
Estonian: Üldiselt on inhaleeritavad kortikosteroidid jätkuvalt enamiku patsientide esmavaliku ravi.
English: This could make your breathing worse.
Estonian: See võib hingamisraskusi süvendada.
English: Teva Eesti esindus UAB Sicor Biotech Eesti
Estonian: Eesti Teva Eesti esindus UAB Sicor Biotech Eesti
English: After 12 weeks no children in either treatment arm had abnormally low 24-hour urinary cortisol excretion.
Estonian: Pärast 12 nädalat ei olnud ühelgi lapsel uriini ebanormaalselt madalat kortisoolisisaldust 24 tunni jooksul.
English: The secondary endpoints in the table above reached statistical significance in the whole population.)
Estonian: Ülaltoodud tabelis esitatud teisesed tulemusnäitajad saavutasid kõigis ravirühmades statistilise olulisuse piiri.)
English: Both non-selective and selective β blockers should be avoided unless there are compelling reasons for their use.
Estonian: Vältida tuleb nii mitteselektiivseid kui selektiivseid β-blokaatoreid, v.a juhul, kui nende kasutamine on möödapääsmatu.
English: However, these animal experimental results do not seem to be relevant for man given recommended doses.
Estonian: Sellegipoolest ei näi nende loomkatsete tulemused soovitatud annuste kasutamisel inimestele tähtsust omavat.
English: Reported over 3 years in a COPD study
Estonian: Teatatud 3-aastases KOK-uuringus osalemise ajal
English: If you are not using Aerivio Spiromax properly and/or you are not breathing in forcefully enough, this may mean that you are not getting enough of the medicine into your lungs.
Estonian: Kui te ei kasuta Aerivio Spiromax'i õigesti ja/või te ei hinga sisse piisavalt tugevalt, võib see tähendada, et teie kopsudesse ei jõua piisavalt ravimit.
English: The effects include: Slowing of growth in children and adolescents
Estonian: Sellega kaasnevad järgmised kõrvaltoimed: kasvu aeglustumine lastel ja noorukitel,
English: Survival status at 3 years was determined for all patients regardless of withdrawal from study medication.
Estonian: Elulemust hinnati 3. aastal kõigil patsientidel, sõltumata uuringuravimi võtmise katkestamisest.
English: Health Related Quality of Life, as measured by the St George's Respiratory Questionnaire (SGRQ) was improved by all active treatments in comparison with placebo.
Estonian: Tervisega seotud elukvaliteet, mida hinnati St Georgi hingamisteede küsimustiku (St George's Respiratory Questionnaire, SGRQ) alusel, paranes kõigi aktiivsete ravide toimel võrreldes platseeboga.
English: After opening the foil wrap: 3 months.
Estonian: Kõlblikkusaeg pärast fooliumpakendi esmast avamist: 3 kuud.
English: Do not take more than the recommended dose.
Estonian: Ärge ületage soovitatavat annust.
English: Consideration should be given to referring the child or adolescent to a paediatric respiratory specialist.
Estonian: Kaaluda tuleb lapse või nooruki saatmist laste hingamisteede spetsialisti juurde.
English: Keep taking it until your doctor tells you to stop.
Estonian: Jätkake raviga, kuni arst käsib teil kasutamise lõpetada.
English: Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics, ATC code: R03AK06
Estonian: Farmakoterapeutiline rühm: hingamisteede obstruktiivsete haiguste raviks kasutatavad ained, adrenergilised ained kombinatsioonis kortikosteroidide või teiste ainetega, v.a antikolinergilised, ATC-kood: R03AK06
English: Packs of 1 and 3 inhalers.
Estonian: Pakendid 1 ja 3 inhalaatoriga.
English: • Tuberculosis (TB) now or have had in the past, or have other lung infections
Estonian: • tuberkuloos, hetkel või anamneesis, või kui teil on muud kopsuinfektsioonid.
English: • Aerivio Spiromax may affect the normal production of steroid hormones in the body, particularly if you have taken high doses for long periods of time.
Estonian: • Aerivio Spiromax võib mõjutada steroidhormoonide normaalset tootmist organismis, eriti juhul, kui seda kasutatakse pika ajaperioodi jooksul.
English: You may notice your heart beating faster than usual and that you feel shaky.
Estonian: Te võite märgata, et süda lööb kiiremini kui tavaliselt ja tekib värisemistunne.
English: Beta adrenergic blockers may weaken or antagonise the effect of salmeterol.
Estonian: Beeta-adrenergilised blokaatorid võivad salmeterooli toimet nõrgendada või blokeerida.
English: Some medicines may increase the effects of Aerivio Spiromax and your doctor may wish to monitor you carefully if you are taking these medicines (including some medicines for HIV: ritonavir, cobicistat).
Estonian: Mõni ravim võib suurendada Aerivio Spiromax'i toimet ja teie arst võib soovida teid hoolikalt jälgida, kui te neid ravimeid võtate (sh HIV-ravimid: ritonaviir, kobitsistaat).
English: Suomi/Finland Teva FinlandPuh/Tel: +358 20 180 5900
Estonian: Suomi/Finland Teva Finland Puh/Tel: +358 20 180 5900
English: This does not need emergency action as adrenal function is recovered in a few days, as verified by plasma cortisol measurements.
Estonian: See ei vaja esmaabi, kuna neerupealiste funktsioon taastub mõne päevaga, mida kinnitavad plasma kortisoolisisalduse mõõtmise andmed.
English: βeta 2 adrenoreceptor agonists
Estonian: Beeta-2-adrenoretseptori agonistid
English: You may notice a taste when you take your inhalation.
Estonian: Võite inhaleerimisel tunda maitset.
English: If you are using Aerivio Spiromax for asthma, your doctor will want to check your symptoms regularly.
Estonian: Kui kasutate Aerivio Spiromax'i astma raviks, soovib arst regulaarselt teie sümptomeid kontrollida.